YOU ARE HERE:
New drugs news
page  of 15
 
Headline
Date
  New hepatitis C protease inhibitors achieve 80% ‘cure’ rate in patients with genotype 1 infection
03.11.09
  FDA committee recommends approval of maraviroc for first-line treatment in US
09.10.09
  Maturation inhibitor bevirimat is well tolerated and effective in predicted responders
18.09.09
  Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression
18.09.09
  Nutritional formula linked to reduced CD4 cell loss in untreated people
17.09.09
  GSK's second integrase inhibitor looks potent and well-tolerated in early study
17.09.09
  IL-7 may boost CD4 and CD8 T-cells, study shows
17.09.09
  Raltegravir moves closer to approval for first-line use in Europe
27.07.09
  Experimental integrase inhibitor GSK-572 looks good in early studies
22.07.09
  Once-daily Kaletra as safe and effective as twice-daily dosing
22.07.09
  TB Alliance, Tibotec, form partnership to take forward new drug
17.06.09
  New hepatitis C drug may halve the length of treatment, but ribavirin still needed
12.06.09
  New drug for MDR-TB does well in trial
09.06.09
  `Shock and kill` approach awakens latent HIV in test tube
05.06.09
  Glaxo to test rival's protease inhibitor, re-engineered to last longer
02.06.09
  Raltegravir shows potential for use as PrEP drug
28.04.09
  GSK and Pfizer HIV divisions to form new company
17.04.09
  Breakthrough in XDR-TB research could lead to two-drug treatment
26.02.09
  Two novel ‘enhancer’ drugs boost protease inhibitors as much as ritonavir
10.02.09
  Panacos sells its first-in-class maturation inhibitor
22.01.09

page  of 15